E3 ubiquitin-protein ligase RLIM (RLIM (also commonly referred to as RNF12))

E3 ubiquitin-protein ligase RLIM (commonly abbreviated RLIM, also known as RNF12) is a nuclear-localized enzyme that attaches ubiquitin to substrate proteins, targeting them for degradation via the proteasome. RLIM possesses a C-terminal RING-H2 zinc finger domain conferring its ligase activity, and interacts with LIM-domain transcription factors as both a coactivator and coregulator. It plays critical roles in gene regulation, especially as a central activator of X chromosome inactivation (XCI) through degradation of the Rex1 repressor protein in female embryonic cells. RLIM modulates a range of substrates including HDAC2, TRF1, estrogen receptor α, and others, impacting transcriptional activity, cell migration, and cell survival — notably in the mammary gland during pregnancy and lactation. Mutations in RLIM/RNF12 can result in developmental syndromes and may be involved in cancer biology, but no drugs currently target this enzyme in clinical settings

Other names

RNF12R-LIMNY-REN-43MGC15161LIM domain-interacting RING finger proteinRING finger LIM domain-binding proteinRING finger protein 12ring zinc finger LIM domain binding proteinring zinc finger protein NY-REN-43 antigenTOKASMRX61E3 ubiquitin-protein ligase RNF12

Drug modulation of RLIM would theoretically involve alteration of its E3 ubiquitin ligase activity, affecting substrate protein ubiquitination and degradation.\nInhibition could impact cell cycle progression, transcriptional regulation, and XCI.\nNo clinically validated RLIM modulators are known; mechanism is hypothetical at present